<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01588418</url>
  </required_header>
  <id_info>
    <org_study_id>233-GAS-08</org_study_id>
    <nct_id>NCT01588418</nct_id>
  </id_info>
  <brief_title>Acute Effect of Exenatide on Brain Glucose Metabolism</brief_title>
  <official_title>Effect of Exenatide on Brain Glucose Uptake in Relations to Pancreatic, Adipose Tissue, and Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amylin Pharmaceuticals, LLC.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study will examine brain glucose metabolism after an overnight fast to
      determine the effect of exenatide on brain glucose metabolism and lipid metabolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will elucidate if exenatide has an effect on brain glucose metabolism. This will
      be accomplished by measuring the rate of glucose binding in various brain regions by Positron
      Emission Tomography (PET) after glucose load with exenatide injection and compare it with
      placebo injection measured in the same subject. The changes will be compared with peripheral
      and hepatic glucose metabolism and lipolysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Exenatide on Brain (Total Gray Matter) Glucose Metabolism</measure>
    <time_frame>120 minutes after exenatide or placebo injection</time_frame>
    <description>To study the acute effect of exenatide on brain glucose metabolism after the glucose load. Brain glucose uptake will be determined from serial FDG PET-imaging, by using graphical methods to quantify both global and regional results. The results obtained after Exenatide injection will be compared with the ones obtained after injection of placebo in the same subject.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Exenatide on the Liver and Adipose Tissue Glucose Uptake</measure>
    <time_frame>60 minutes after exenatide or placebo injection</time_frame>
    <description>we evaluated the acute effects of exenatide on hepatic (Hep-IR) and adipose (Adipo-IR) insulin resistance and glucose uptake.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Impaired Glucose Tolerance (IGT)</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Exenatide first, then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exenatide 5mcg was injected subcutaneously 30 min before Oral Glucose Tolerance Test (OGTT)-PET study. The same subject was studied again a few weeks later with the same protocol with Placebo injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo first, then Exenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo was injected subcutaneously 30 min before OGTT-PET study. The same subject was studied again a few weeks later with the same protocol with injection of Exenatide 5mcg .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>Exenatide (5mcg) was administered in random order 30 min before OGTT-PET study, crossover study</description>
    <arm_group_label>Exenatide first, then Placebo</arm_group_label>
    <arm_group_label>Placebo first, then Exenatide</arm_group_label>
    <other_name>Byetta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo was administered in random order 30 min before OGTT-PET study in the same subject</description>
    <arm_group_label>Exenatide first, then Placebo</arm_group_label>
    <arm_group_label>Placebo first, then Exenatide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males age 18-65 years old

          2. Patients must have Body Mass Index (BMI) between 25 and 40 kg/m2

          3. 2-hour glucose concentration above 140mg/dl after 75g glucose load, ie, having
             impaired glucose tolerance or newly diagnosed type 2 diabetes.

          4. Patients must have BMI of 25-40 kg/m2

          5. Patients must have no known severe liver or kidney disease, cancer, neurologic,
             psychiatric or systemic disease, ability to understand the study.

          6. Only patients whose body weight has been stable (±3-4 pounds) over the three months
             prior to study will be included.

          7. Patients must have the following laboratory values:

               -  Hematocrit ≥ 34 vol%

               -  Serum creatinine* ≤ 1.5 mg/dl in males and

               -  Aspartate aminotransferase (AST) serum glutamic oxaloacetic transaminase (SGOT):
                  ≤ 2.5 times upper limit of normal

               -  Alanine aminotransferase (ALT) serum glutamic pyruvic transaminase (SGPT): ≤ 2.5
                  times upper limit of normal

               -  Alkaline phosphatase ≤ 2.5 times upper limit of normal

               -  If serum creatinine is ≤ 1.5 mg/dl in males, the PI can grant an exception and
                  not exclude the patient if the Glomerular filtration rate (GFR) is &gt;70 ml/min

        Exclusion Criteria:

        Patients are excluded from participation in the study if they meet any of the following
        criteria:

          1. Patients with major chronic illness (cancer, liver, kidney, cardiovascular disease)

          2. Patients with BMI over 40 and under 25

          3. Patient with age below 18 yrs and over 65 yrs

          4. Female subjects

          5. Patients with type 1 diabetes

          6. Patients treated for type 2 diabetes

          7. Subjects with normal glucose tolerance (NGT)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amalia Gastaldelli, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UTHSCSA, San Antonio, TX</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Diabetes Institute and UTHSCSA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Daniele G, Iozzo P, Molina-Carrion M, Lancaster J, Ciociaro D, Cersosimo E, Tripathy D, Triplitt C, Fox P, Musi N, DeFronzo R, Gastaldelli A. Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System. Diabetes. 2015 Oct;64(10):3406-12. doi: 10.2337/db14-1718. Epub 2015 Jun 26.</citation>
    <PMID>26116695</PMID>
  </results_reference>
  <results_reference>
    <citation>Gastaldelli A, Gaggini M, Daniele G, Ciociaro D, Cersosimo E, Tripathy D, Triplitt C, Fox P, Musi N, DeFronzo R, Iozzo P. Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study. Hepatology. 2016 Dec;64(6):2028-2037. doi: 10.1002/hep.28827.</citation>
    <PMID>27639082</PMID>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2012</study_first_submitted>
  <study_first_submitted_qc>April 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2012</study_first_posted>
  <results_first_submitted>October 28, 2015</results_first_submitted>
  <results_first_submitted_qc>April 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 25, 2017</results_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Ralph DeFronzo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Impaired glucose tolerance (IGT)</keyword>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>OGTT-PET: Exenatide First Then Placebo</title>
          <description>In the first study subjects received exenatide 5ug injected before OGTT-PET. In the second study (3 to 12 wk after first study), subjects received placebo injection before OGTT-PET</description>
        </group>
        <group group_id="P2">
          <title>OGTT-PET: Placebo First, Then Exenatide</title>
          <description>In the first study subjects received placebo injected before OGTT-PET. In the second study (3 to 12 wk after first study), subjects received exenatide injection (5ug) before OGTT-PET</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>We studied male subjects with impaired fasting glucose or newly diagnosed type 2 diabetes.</population>
      <group_list>
        <group group_id="B1">
          <title>PET With Exenatide vs Placebo Injection</title>
          <description>All subjects will receive the same intervention with Exenatide and placebo. Exenatide or placebo will be administered in random order, (i.e. first or second before OGTT-PET study).
In the first study IGT male subjects will be randomized to exenatide or placebo injection before OGTT-PET study. In the second study the same subjects will receive placebo or exenatide respectively before OGTT-PET study. The results obtained after Exenatide injection will be compared with the ones obtained after injection of placebo in the same subject.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (Body Mass Index)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting plasma glucose</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>% of total hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.6" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>2 hour plasma glucose concentration</title>
          <description>glucose concentration at 2h during screening OGTT</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect of Exenatide on Brain (Total Gray Matter) Glucose Metabolism</title>
        <description>To study the acute effect of exenatide on brain glucose metabolism after the glucose load. Brain glucose uptake will be determined from serial FDG PET-imaging, by using graphical methods to quantify both global and regional results. The results obtained after Exenatide injection will be compared with the ones obtained after injection of placebo in the same subject.</description>
        <time_frame>120 minutes after exenatide or placebo injection</time_frame>
        <population>We studied, in the same subject, the acute effect of injection of exenatide vs placebo on brain glucose metabolism (CMRglu) after the glucose load. We used FDG PET-imaging to quantify global and regional results.</population>
        <group_list>
          <group group_id="O1">
            <title>Effect of Exenatide or Placebo on CMRglu</title>
            <description>Brain glucose metabolism (CMRglu) during OGTT measured by PET w/ or w/out Exenatide injection</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Exenatide on Brain (Total Gray Matter) Glucose Metabolism</title>
          <description>To study the acute effect of exenatide on brain glucose metabolism after the glucose load. Brain glucose uptake will be determined from serial FDG PET-imaging, by using graphical methods to quantify both global and regional results. The results obtained after Exenatide injection will be compared with the ones obtained after injection of placebo in the same subject.</description>
          <population>We studied, in the same subject, the acute effect of injection of exenatide vs placebo on brain glucose metabolism (CMRglu) after the glucose load. We used FDG PET-imaging to quantify global and regional results.</population>
          <units>μmol/(ml*min)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>total gray matter CMRglu after Exenatide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total gray matter CMRglu after Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Exenatide on the Liver and Adipose Tissue Glucose Uptake</title>
        <description>we evaluated the acute effects of exenatide on hepatic (Hep-IR) and adipose (Adipo-IR) insulin resistance and glucose uptake.</description>
        <time_frame>60 minutes after exenatide or placebo injection</time_frame>
        <population>Outcome data was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide First, Then Placebo</title>
            <description>Exenatide 5mcg was injected subcutaneously 30 min before Oral Glucose Tolerance Test (OGTT)-PET study. The same subject was studied again a few weeks later with the same protocol with Placebo injection.
Exenatide: Exenatide (5mcg) was administered in random order 30 min before OGTT-PET study, crossover study
Placebo: Placebo was administered in random order 30 min before OGTT-PET study in the same subject</description>
          </group>
          <group group_id="O2">
            <title>Placebo First, Then Exenatide</title>
            <description>Placebo was injected subcutaneously 30 min before OGTT-PET study. The same subject was studied again a few weeks later with the same protocol with injection of Exenatide 5mcg .
Exenatide: Exenatide (5mcg) was administered in random order 30 min before OGTT-PET study, crossover study
Placebo: Placebo was administered in random order 30 min before OGTT-PET study in the same subject</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Exenatide on the Liver and Adipose Tissue Glucose Uptake</title>
          <description>we evaluated the acute effects of exenatide on hepatic (Hep-IR) and adipose (Adipo-IR) insulin resistance and glucose uptake.</description>
          <population>Outcome data was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PET With Exenatide or Placebo Injection</title>
          <description>This is a crossover study where all subjects received the same intervention with Exenatide and placebo, acutely in random order, (i.e. first or second before OGTT-PET study).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Our study has several potential limitations. It included only men. During OGTT it is difficult to evaluate the separate contributions of glucose and insulin.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Ralph DeFronzo</name_or_title>
      <organization>University of Texas Health Science Center at San Antonio</organization>
      <phone>210-567-6691</phone>
      <email>defronzo@uthscsa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

